Regulatory

Regulatory

Japan's PMDA and Tigilanol Tiglate: Regulatory Considerations for EBC-46 in Asia-Pacific Markets

An overview of how Japan's Pharmaceuticals and Medical Devices Agency evaluates novel botanical compounds and what this means for tigilanol tiglate.

Regulatory

EMA Scientific Advice and EBC-46: What Europe’s Regulatory Pathway Looks Like in 2026

An overview of how the European Medicines Agency scientific advice process applies to tigilanol tiglate and what it means for EBC-46 regulation in Europe.

Regulatory

Health Canada and EBC-46: How Canada's Natural Health Products Regulations Apply to Blushwood Berry Supplements

Canada regulates blushwood berry extract under its Natural Health Products framework — a structured pathway that requires product licencing, site licencing, and evidence of safety before market entry.

Regulatory

EBC-46 in 2026: A Snapshot of the Global Regulatory Landscape

A neutral overview of where EBC-46 sits across veterinary approvals, human clinical development, and the US dietary supplement framework as of April 2026.

Regulatory

EBC-46 Regulatory Landscape 2026: Stelfonta Approvals and DSHEA Framework

How tigilanol tiglate is regulated across jurisdictions — from FDA veterinary approval of Stelfonta to DSHEA's established framework for botanical dietary supplements.

Regulatory

EBC-46 Regulatory Landscape 2026: From Veterinary Approval to Human Supplement Frameworks

An overview of the regulatory milestones for tigilanol tiglate, from Stelfonta veterinary approval to human clinical pathways and DSHEA supplement frameworks.

Regulatory

Australia's TGA and EBC-46: How Therapeutic Goods Regulation Coexists with Dietary Supplement Markets

Australia's TGA regulates therapeutic goods but dietary supplements operate under a distinct framework. Understanding these categories clarifies how EBC-46 products navigate compliance.

Regulatory

Novel Food Regulations and EBC-46: How the EU and UK Classify Emerging Botanical Extracts

How EU and UK Novel Food regulations apply to botanical extracts like EBC-46, and what the classification process means for supplement availability.

Regulatory

International Supplement Notification Systems: How EBC-46 Products Navigate Global Market Entry

Different countries require different notification procedures for botanical supplements. Understanding these systems helps buyers evaluate which products have met their local standards.

Regulatory

DSHEA at 30: Why EBC-46 Botanical Supplements Remain Fully Legal Under Federal Law

The Dietary Supplement Health and Education Act provides the established legal framework under which botanical EBC-46 supplements are manufactured and sold in the United States.

Regulatory

EBC-46 Supplements and Dietary Supplement Regulation: How Reputable Brands Comply

Understanding the DSHEA framework — and what responsible blushwood berry extract brands do to operate within it — helps buyers identify quality suppliers.

Regulatory

Clinical Hold and Safety Review: How the FDA Monitors EBC-46 Trial Progress

The FDA can pause any clinical trial through a clinical hold order. Here is how that oversight mechanism applies to intratumoral EBC-46 research.